I-Darifenacin Hydrobromide Darifenacin HBr CAS 133099-07-7 Assay ≥99.0% I-API Factory High Quality
Ubonelelo lwabavelisi ngoBusulungekileyo obuPhezulu kunye noMgangatho oZinzileyo
Igama leKhemikhali: I-Darifenacin Hydrobromide
CAS: 133099-07-7
I-Darifenacin hydrobromide yinto ekhethiweyo ye-M3 ye-muscarinic receptor antagonist esetyenziselwa ukunyanga ukungabikho komchamo kunye ne-overactive bladder syndrome.
Umgangatho ophezulu we-API, iMveliso yoRhwebo
| Igama leMchiza | I-Darifenacin Hydrobromide |
| Izithethantonye | UDarifenacin HBr;UK-88525;Vulelax |
| Inombolo yeCAS | 133099-07-7 |
| Inombolo yeCAT | RF-API94 |
| Ubume beStokhwe | Kwi-Stock, iMveliso yeMveliso ukuya kumakhulu eeKilogram |
| Ifomula yeemolekyuli | I-C28H30N2O2.HBr |
| Ubunzima beMolekyuli | 507.46 |
| Indawo yokunyibilika | 228.0 ~ 230.0℃ |
| Ukunyibilika | I-DMSO: I-Soluble 20mg / ml, Icacile |
| Ubushushu boGcino | Gcina Ixesha elide kwi -20 ℃ |
| Uphawu | Ruifu Chemical |
| Into | Iinkcukacha |
| Imbonakalo | Umgubo weCrystalline oMhlophe |
| Ukunyibilika | Inyibilika kancinane kwiMethanol, iNyibilika kancinane emanzini kwaye ayinyibiliki kwiChloroform |
| Ukuchongwa kwe-IR | I-Spectrum yesampuli ihambelana naleyo yomgangatho wereferensi |
| Ukuchongwa kwe-HPLC | Ixesha lokugcinwa kwencopho enkulu yesisombululo sesampulu sihambelana nesisombululo esiqhelekileyo |
| Izinto ezinxulumeneyo | |
| Max.Ukungacoceki Okukodwa | ≤0.50% |
| Ukungcola ngokupheleleyo | ≤1.0% |
| Isomer ye-Optical | ≤0.50% |
| Izinyibilikisi ezishiyekileyo | |
| I-Ethyl Acetate | ≤0.50% |
| I-Ethanol | ≤0.50% |
| IMethanol | ≤0.30% |
| I-acetone | ≤0.50% |
| 1-Butanol | ≤0.50% |
| Ilahleko ekomisweni | ≤1.0% (Yoma kwi-105℃ kwi-dryer yombane evuthela umoya kude kube nobunzima obuqhubekayo) |
| Intsalela kwi-Ignition | ≤0.10% |
| Iintsimbi ezinzima | ≤20ppm |
| Isivavanyi | ≥99.0% (kwisiseko somisiwe) |
| Beka ubomi kwishelufa | Iinyanga ezingama-24 |
| Umgangatho woVavanyo | Umgangatho woShishino |
| Ukusetyenziswa | I-API, I-Overactive Bladder |
Iphakheji: Ibhotile, ingxowa yefoyile yeAluminiyam, igubu lekhadibhodi, 25kg/Igubu, okanye ngokwemfuno yomthengi.
Imeko yoGcino:Gcina kwizikhongozeli ezivaliweyo kwindawo epholileyo neyomileyo;Khusela ekukhanyeni, ukufuma kunye nokuhlaselwa zizinambuzane.
I-Darifenacin Hydrobromide, i-Darifenacin HBr (i-CAS 133099-07-7), i-oral esebenzayo, kanye ngosuku i-M3 receptor antagonist ekhethiweyo, yaqaliswa ukunyangwa kwe-bladder esebenzayo kwizigulane ezineempawu zokungaphumeleli komchamo, ukukhawuleza kunye nokuphindaphinda.Isiyobisi sithintela ngokukhethekileyo i-M3 receptor kwi-muscle detrusor ngelixa igcina i-M1 kunye ne-M2 i-receptors ekukholelwa ukuba ibandakanyeka kwinkqubo ye-nervous central kunye nomsebenzi we-cardiovascular ngokulandelanayo.Ikhompawundi yaphuhliswa kuqala yiPfizer kwaye inelayisensi eNovartis naseBayer.
